Evidence map›Paper›PMID 32394101›Full record

ArticleEuropean biophysics journal : EBJ2020

New insights into novel Escherichia coli colistin-resistant strains isolated from Argentina.

Patricia Maturana, Melina Martinez, Diego Faccone, Liliana Semorile, Paulo C Maffia, Axel Hollmann

Open access · greenAbstract read
PubMed Publisher
In one paragraph

Article in European biophysics journal : EBJ, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 55% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Patricia MaturanaLaboratorio de Compuestos Bioactivos, Centro de Investigaciones en Biofísica Aplicada y Alimentos (CIBAAL), CONICET, Universidad Nacional de Santiago del Estero, RN 9, Km 1125, 4206, Santiago del Estero, Argentina.
Melina MartinezLaboratorio de Microbiología Molecular, Instituto de Microbiología Básica y Aplicada, Universidad Nacional de Quilmes, Roque Saenz Peña 352, B1876BXD, Bernal, Argentina.
Diego FacconeServicio Antimicrobianos, Instituto Nacional de Enfermedades Infecciosas-ANLIS "Dr. Carlos G. Malbrán", Av. Velez Sarsfield 563, C1282AFF, Buenos Aires, Argentina.
Liliana SemorileLaboratorio de Microbiología Molecular, Instituto de Microbiología Básica y Aplicada, Universidad Nacional de Quilmes, Roque Saenz Peña 352, B1876BXD, Bernal, Argentina.
Paulo C MaffiaLaboratorio de Microbiología Molecular, Instituto de Microbiología Básica y Aplicada, Universidad Nacional de Quilmes, Roque Saenz Peña 352, B1876BXD, Bernal, Argentina.
Axel HollmannLaboratorio de Compuestos Bioactivos, Centro de Investigaciones en Biofísica Aplicada y Alimentos (CIBAAL), CONICET, Universidad Nacional de Santiago del Estero, RN 9, Km 1125, 4206, Santiago del Estero, Argentina. ahollmann@gmail.com.
Consejo Nacional de Investigaciones Científicas y Técnicas · ARNational University of Quilmes · ARAdministración Nacional de Laboratorios e Institutos de Salud · AR

Funding

Consejo Nacional de Investigaciones Científicas y Técnicas 11220130100383COFondo para la Investigación Científica y Tecnológica PICT 2016-0478Fondo para la Investigación Científica y Tecnológica PICT 2017-2349Universidad Nacional de Santiago del Estero PI-UNSE 23/A250
6 · The paper itself

Abstract

Colistin is a polymyxin antibiotic (polymyxin E) that has in recent years re-emerged as an option for treatment of multidrug-resistant bacteria. Recently, the re-introduction of colistin resulted in the appearance of colistin-resistant bacteria, which is usually caused by LPS modifications. The fact that this modification is mediated by a plasmid carrying the mcr-1 gene, implies a horizontal transfer of colistin resistance. In Argentina, the National Reference Laboratory in Antimicrobial Resistance (NRLAR), has recently screened several bacteria for the MCR-1 plasmid, detecting nine Escherichia coli isolates carrying the plasmid with the mcr-1 gene, among others. In this context, we proposed to assess the effect of surface charge modifications induced by the plasmid MCR-1 and its impact on the resulting colistin resistance in two clinical isolates of colistin-resistant E. coli. Using zeta potential assays, we confirmed the reduction of negative charge exposure on clinical isolates compared to the reference strain of E. coli. In addition, through permeabilization assays, we were able to correlate this reduction in charge exposure with the extent of damage to the bacterial membrane. The fact that this surface charge modification through substitution of lipid A is plasmid encoded, represents an important concern for future antimicrobial peptide drug development.

Indexed as

Drug Resistance, BacterialArgentinaCell Membrane PermeabilityColistinEscherichia coliHumansColistinColistinMembrane permeabilityPotential zetaResistance

Identifiers

PMID32394101
OpenAlexW3024546313

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.